One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
About this trial
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.
Eligibility criteria
Qualifiers
Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma
Planned peripheral blood sampling +/- bone marrow aspiration
Age > 18 years
Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.
Disqualifiers
Undefined monoclonal gammopathy or non-AL amyloidosis
Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy
Age <18 years
Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov